May 26, 2021 10:20 AM EDT

Under-the-radar NiKang Therapeutics bursts onto the scene with $200M Series C from investors that screams IPO

Max Gelman

Senior Editor

A secretive biotech out of Wilmington, DE, closed a massive, nine-figure Series C on Wednesday, and it comes from an investor syndicate that is highly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Under-the-radar NiKang Therapeutics bursts onto the scene with $200M Series C from investors that screams IPO

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Bristol Myers reveals more job cuts in New Jersey

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Un­der-the-radar NiKang Ther­a­peu­tics bursts on­to the scene with $200M Se­ries C from in­vestors that screams IPO

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Under-the-radar NiKang Therapeutics bursts onto the scene with $200M Series C from investors that screams IPO

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Bristol Myers reveals more job cuts in New Jersey

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial